Given its importance in melanoma progression, we explored whether Gal-3 across various concentrations (0.02, 0.1, 0.5, and 1 μg/mL) influences this pathway and how its effects differ in the presence or absence of GCNT2/I-branching. This evidence concerns the gene LGALS3 and melanoma.